siRNA Agents Targeting E2 and nsP1 Genes for Chikungunya Virus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective solutions for inhibiting Chikungunya virus replication, particularly in vivo, despite some in vitro successes with siRNAs targeting specific genes like E1 and nsP1, with no comprehensive antiviral strategy available for this mosquito-transmitted alphavirus.
Innovation Solution
Development of siRNA agents specifically targeting the E2 gene and optionally the nsP1 gene of Chikungunya virus, designed to inhibit viral protein and mRNA production, using a combination of siRNAs (NIVsi-1 and NIVsi-5) for in vitro and in vivo applications, formulated with Hiperfect Transfection reagent for enhanced delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNA agents are introduced into cells to inhibit Chikungunya virus replication, then viral replication is reduced, but the therapy has not been successfully evaluated in vivo
Solution Approach 1:
The patent performs preliminary optimization of siRNA design, transfection conditions, and dosage regimens in vitro before in vivo evaluation. This preliminary action ensures that the siRNA agents are properly configured and tested under controlled conditions, establishing a foundation for subsequent in vivo applications and reducing the risks associated with translational evaluation.
2Reliability
If siRNA agents target multiple viral genes (E2 and nsP1), then comprehensive viral inhibition is achieved, but the complexity of the therapeutic strategy increases
Solution Approach 1:
The patent divides the antiviral strategy into multiple targeted components, with separate siRNA agents designed to specifically target different viral genes (E2 and nsP1). This segmentation allows each siRNA to focus on a specific viral function, and the combination provides comprehensive coverage of viral replication pathways while maintaining manageable complexity through modular design.
Solution Approach 2:
The patent combines multiple siRNA agents targeting different viral genes into a single therapeutic regimen. This merging of targeted approaches creates a synergistic effect where the combination of siRNAs against E2 and nsP1 provides more comprehensive viral inhibition than single-target approaches, while the agents work together in a coordinated manner.
3Reliability
If high concentrations of siRNA are used to maximize viral inhibition, then replication reduction is enhanced, but potential off-target effects and cytotoxicity increase
Solution Approach 1:
The patent systematically optimizes siRNA concentration parameters to identify the minimum effective dose that achieves sufficient viral inhibition while minimizing off-target effects. By adjusting and refining the concentration parameter through dose-response studies, the patent establishes an optimal dosage range that balances therapeutic efficacy with safety, avoiding both under-dosing and excessive cytotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA agents significantly reduce Chikungunya virus titers by 5-7 log orders in both cell cultures and infected mice, demonstrating potent inhibition and potential therapeutic efficacy against Chikungunya virus infection.
Implementation Method 1
RNA interference (RNAi) is the process of sequence specific Post Transcriptional Gene Silencing (PTGS) in Eukaryotes. In RNAi, long dsRNA and miRNA precursors are processed to small interfering RNA (siRNA) /microRNA duplexes by the RNase-III-like enzyme Dicer. The siRNA/miRNA duplexes thus formed then binds with other components in cell to form a nucleic acid-protein complex called RNA-induced silencing complex (RISC). The activated RISC targets a homologous mRNA by base pairing, resulting in the cleavage and degradation of the mRNA inhibiting cell-specific gene expression.
Data Source
Figure 1~2
Figure 3A~3C
Figure 4A~4B
AI summary
The present invention relates to RNAi agents for inhibition of Chikungunya virus are described herein. The present invention provides RNAi agents for inhibition of Chikungunya virus, particularly by targeting the E2 gene and nsPl gene or both of the Chikungunya virus; the RNAi agents comprising of the entire nucleotide sequence set forth is SEQ ID 1 or SEQ ID 5 or combination thereof; or comprising of 15 or more contiguous nucleotides as set forth is SEQ ID 1 or SEQ ID 5 or combination thereof along with the addition nucleotides from the contiguous region of the E2 and nsPl target gene. The invention further provides a RNAi composition for reducing the E2 protein and nsPl protein level of Chikungunya virus and inhibition of Chikungunya virus replication. The combination of RNAi agents provides an excellent therapeutic composition for treatment of Chikungunya virus infection.